Correspondence 0001493152-23-000915 from Immix Biopharma, Inc. (IMMX)

Immix Biopharma, Inc.
Date: Jan. 9, 2023 · CIK: 0001873835 · Accession: 0001493152-23-000915

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-269100

Date

Jan. 9, 2023

Author

IMMIX

Form

CORRESP

Company

Immix Biopharma, Inc.

Letter

Immix Biopharma, Inc.

West Olympic Blvd., Suite 200

Los Angeles, CA 90064

January 9, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Attention: Lauren Hamill

Re: Immix Biopharma, Inc.

Registration Statement on Form S-3

File No. 333-269100

Filed January 3, 2023

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Immix Biopharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on Wednesday, January 11, 2023, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Please notify Jeffrey Fessler of Sheppard Mullin Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

Very
truly yours,
IMMIX
BIOPHARMA, INC.

Show Raw Text

CORRESP
1
filename1.htm

Immix
Biopharma, Inc.

11400
West Olympic Blvd., Suite 200

Los
Angeles, CA 90064

January
9, 2023

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
Lauren Hamill

    Re:
    Immix
    Biopharma, Inc.

    Registration
    Statement on Form S-3

    File
    No. 333-269100

    Filed
    January 3, 2023

Ladies
and Gentlemen:

Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Immix Biopharma,
Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated
so that it will become effective at 4:30 p.m., Eastern Time, on Wednesday, January 11, 2023, or as soon thereafter as possible. In
making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Please
notify Jeffrey Fessler of Sheppard Mullin Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as
to the time the Registration Statement has been declared effective pursuant to this acceleration request.

    Very
    truly yours,

    IMMIX
    BIOPHARMA, INC.

    By:
    /s/
    Ilya Rachman

    Name:
    Ilya
    Rachman

    Title:
    CEO

  cc:
  Jeffrey
  Fessler, Sheppard Mullin Richter & Hampton LLP

SecProbe.io